In Duchenne muscular dystrophy (DMD) mice model, the non-steroidal mineralocorticoid receptor antagonist (finerenone) brought significant improvements in clinically relevant functional parameters in skeletal muscle (normalized grip strength, lower susceptibility to limb muscle damage, normalized limb muscle force) (59) (Figure 1). This evidence concerns the gene NR3C2 and Duchenne muscular dystrophy.